Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Meningioma-Brain Crosstalk: A Scoping Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Pathologic Characteristics of Pregnancy-Related Meningiomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Basal Cell Carcinoma of Prostate With MSMB-NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of depression after diagnostic prostate cancer workup - A nationwide, registry-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Docetaxel-a taxane-based chemotherapeutic agent-was the first treatment to demonstrate significant improvements in overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). However, the response to docetaxel is generally short-lived, and relapse eventually occurs due to the development of resistance. To explore the mechanisms of acquired docetaxel resistance in prostate cancer (PCa) and set these in the context of androgen deprivation therapy, we established docetaxel-resistant PCa cell lines, derived from the androgen-dependent LNCaP cell line, and from the LNCaP lineage-derived androgen-independent C4-2B sub-line. We generated two docetaxel-resistant LNCaPR and C4-2BR sub-lines, with IC50 values 77- and 50-fold higher than those of the LNCaP and C4-2B parental cells, respectively. We performed gene expression analysis of the matched sub-lines and found several alterations that may confer docetaxel resistance. In addition to increased expression of ABCB1, an ATP-binding cassette (ABC) transporter, and a well-known gene associated with development of docetaxel resistance, we identified genes associated with androgen signaling, cell survival, and overexpression of ncRNAs. In conclusion, we identified multiple mechanisms that may be associated with the development of taxane drug resistance in PCa. Actioning these mechanisms could provide a potential approach to re-sensitization of docetaxel-resistant PCa cells to docetaxel treatment and thereby further add to the life-prolonging effects of this drug in men with mCRPC.

OriginalsprogEngelsk
Artikelnummer1290
TidsskriftCancers
Vol/bind13
Udgave nummer6
Sider (fra-til)1-20
Antal sider20
ISSN2072-6694
DOI
StatusUdgivet - 14 mar. 2021

ID: 67023945